CEL-SCI's Multikine Demonstrates Promising Tumor Regression, Advances to Confirmatory Phase 3 Trial for Head and Neck Cancer

CEL-SCI查看公司主页 Corporation is advancing its investigational cancer therapy, Multikine查看药品详情 (Leukocyte Interleukin, Injection), into a confirmatory Phase 3 registration study following promising results in pre-surgical tumor regression and alignment with FDA on patient selection criteria. The study aims to solidify Multikine's potential as a novel treatment for head and neck cancer (搜索)搜索该疾病, particularly in patients with low PD-L1 (搜索)搜索该靶点 expression.

The FDA has concurred with CEL-SCI查看公司主页's strategy to utilize PD-L1 (搜索)搜索该靶点 expression as a biomarker to identify patients most likely to benefit from Multikine查看药品详情 therapy. This decision is based on data from a previous Phase 3 trial, which demonstrated a 73% 5-year survival rate in patients with low PD-L1 expression treated with Multikine, compared to 45% in the control group (p-value of 0.0015).

Confirmatory Registration Study

CEL-SCI查看公司主页 is initiating a 212-patient confirmatory registration study to further evaluate Multikine查看药品详情 in newly diagnosed, locally advanced head and neck cancer (搜索)搜索该疾病 patients. The study will focus on patients with no lymph node involvement (N0) and low PD-L1 (搜索)搜索该靶点 tumor expression, a population that represents approximately 100,000 patients annually. Full enrollment is anticipated by Q2 2026, with potential for early approval based on pre-surgical response rates.

The design of the Registration Study is based on the prior Phase 3 study results, where Multikine查看药品详情 demonstrated significant rates of tumor regression prior to surgery, a finding not observed in the control group. These pre-surgical tumor regressions, confirmed at surgery, were indicative of a survival benefit. CEL-SCI查看公司主页 believes the study has a high chance of success, with potential for accelerated or conditional approval for Multikine in the coming year, should the pre-surgical tumor responses mirror those seen in the Phase 3 data.

Mechanism of Action and Clinical Rationale

Multikine查看药品详情 is designed to boost the patient's immune system to target the tumor before surgery, radiation, and chemotherapy compromise immune function. The therapy has shown particular promise in patients with low PD-L1 (搜索)搜索该靶点 expression, a population that typically does not respond well to checkpoint inhibitors. CEL-SCI查看公司主页's approach offers a potential new treatment avenue for this subset of head and neck cancer (搜索)搜索该疾病 patients.

Financial Overview

CEL-SCI查看公司主页 reported its fiscal Q1 2025 financial results, with research and development expenses at $4.4 million, consistent with the previous year. The net loss for the quarter was $7.1 million, narrowing to $0.11 per common share, a 21% improvement compared to the prior year. For fiscal year 2024, CEL-SCI reported a net loss of $26.9 million, with R&D expenses of $18.2 million.

Collaboration and Manufacturing

CEL-SCI查看公司主页 has partnered with Ergomed, a clinical research organization (CRO), for the confirmatory registration study. Ergomed previously collaborated with CEL-SCI on the Phase 3 study. CEL-SCI has also completed the commissioning of its cGMP state-of-the-art dedicated manufacturing facility, a key step toward regulatory approval of Multikine查看药品详情.

Study Design

The confirmatory study is titled:

"A Phase III, Open Label, Randomized, Controlled, Multi-Center Study of the Effects of Neoadjuvant Leukocyte Interleukin, Injection (LI) Plus Standard of Care Versus Standard of Care Only in Treatment Naïve Adults With Resectable Locally Advanced Primary Squamous Cell Carcinoma (搜索)搜索该疾病 of the Head and Neck (Oral Cavity) Who Present With No Nodal Involvement and Low Tumor Programmed Death Ligand 1 Expression (Defined as Tumor Proportion Score <10)"

The trial will be conducted across multiple centers in various countries, with the first clinical site expected to open in the United States.